Cohort Study of Chronic Heart Failure

Study Overview
=================
Brief Summary
-----------------
The purpose is to understand the clinical characteristics of chronic heart failure as soon as possible, analyze the etiology, comorbidities, clinical characteristics, and treatment of heart failure patients, observe the gap between real-world clinical practice and guideline recommendations, and provide reference for the improvement of heart failure prevention and treatment in China.

Detailed Description
-----------------
Inclusion criteria: Accompanied by difficulty breathing, fatigue, or decreased activity tolerance; Signs of fluid retention (pulmonary congestion and peripheral edema); Echocardiography shows abnormalities in cardiac structure and/or function; Elevated levels of natriuretic peptide: B-type natriuretic peptide (BNP)>35 ng/L and/or N-terminal B-type proBNP (NT proBNP)>125 ng/L. HF hospitalization recorded within the previous 12 months Exclusion criteria: Concomitant severe liver function, renal failure, or other severe system dysfunction Poor compliance, inability to obtain information, or voluntary refusal to participate in this study.

Official Title
-----------------
Cohort Study of Chronic Heart Failure

Conditions
-----------------
Analyze Etiology, Comorbidities, Clinical Characteristics

Intervention / Treatment
-----------------
* Other: No Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Accompanied by difficulty breathing, fatigue, or decreased activity tolerance; Signs of fluid retention (pulmonary congestion and peripheral edema); Echocardiography shows abnormalities in cardiac structure and/or function; Elevated levels of natriuretic peptide: B-type natriuretic peptide (BNP)>35 ng/L and/or N-terminal B-type proBNP (NT proBNP)>125 ng/L. Exclusion Criteria: Concomitant severe liver function, renal failure, or other severe system dysfunction Poor compliance, inability to obtain information, or voluntary refusal to participate in this study.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention<br>No Intervention | Other: No Intervention<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| echocardiogram | ejection fraction,Consider heart failure when the ejection fraction is less than 50% | Follow up will be conducted at baseline, 6 months, 12 months, and 36 months | 
| cardiac marker | CK，CK-MB，cTnT，cTnI，Mb | Follow up will be conducted at baseline, 6 months, 12 months, and 36 months | 
| serum biochemical indicators | HDL-cholesterol, mg/dL，LDL-cholesterol, mg/dL，Total cholesterol, mg/dL，Triglycerides, mg/dL | Follow up will be conducted at baseline, 6 months, 12 months, and 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thyroid Function | thyroid hormone,Thyroid hormone blood testing: This is the most commonly used method to measure thyroid hormone levels in the blood. Common thyroid hormone indicators include thyroxine, free thyroxine, triiodothyronine, and free triiodothyronine. | Follow up will be conducted at baseline, 6 months, 12 months, and 36 months | 
| Coagulation function indicators | D-Dimer | Follow up will be conducted at baseline, 6 months, 12 months, and 36 months | 
| Blood routine | RBC | Follow up will be conducted at baseline, 6 months, 12 months, and 36 months | 
| Blood routine | WBC | Follow up will be conducted at baseline, 6 months, 12 months, and 36 months | 
| Blood routine | PLT | Follow up will be conducted at baseline, 6 months, 12 months, and 36 months |